cardiovascular-agents and Parkinson-Disease

cardiovascular-agents has been researched along with Parkinson-Disease* in 40 studies

Reviews

1 review(s) available for cardiovascular-agents and Parkinson-Disease

Article	Year
Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development-Review. International journal of molecular sciences, 2021, Mar-13, Volume: 22, Issue:6 Cyclin-dependent kinases (CDKs) are involved in many crucial processes, such as cell cycle and transcription, as well as communication, metabolism, and apoptosis. The kinases are organized in a pathway to ensure that, during cell division, each cell accurately replicates its DNA, and ensure its segregation equally between the two daughter cells. Deregulation of any of the stages of the cell cycle or transcription leads to apoptosis but, if uncorrected, can result in a series of diseases, such as cancer, neurodegenerative diseases (Alzheimer's or Parkinson's disease), and stroke. This review presents the current state of knowledge about the characteristics of cyclin-dependent kinases as potential pharmacological targets. Topics: Alzheimer Disease; Animals; Antineoplastic Agents; Apoptosis; Cardiomegaly; Cardiovascular Agents; Cell Cycle; Cyclin-Dependent Kinases; Cyclins; Gene Expression Regulation; Humans; Neoplasms; Neuroprotective Agents; Parkinson Disease; Protein Kinase Inhibitors; Saccharomyces cerevisiae; Stroke	2021

Article

Year

Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development-Review.

International journal of molecular sciences, 2021, Mar-13, Volume: 22, Issue:6

Cyclin-dependent kinases (CDKs) are involved in many crucial processes, such as cell cycle and transcription, as well as communication, metabolism, and apoptosis. The kinases are organized in a pathway to ensure that, during cell division, each cell accurately replicates its DNA, and ensure its segregation equally between the two daughter cells. Deregulation of any of the stages of the cell cycle or transcription leads to apoptosis but, if uncorrected, can result in a series of diseases, such as cancer, neurodegenerative diseases (Alzheimer's or Parkinson's disease), and stroke. This review presents the current state of knowledge about the characteristics of cyclin-dependent kinases as potential pharmacological targets.

Topics: Alzheimer Disease; Animals; Antineoplastic Agents; Apoptosis; Cardiomegaly; Cardiovascular Agents; Cell Cycle; Cyclin-Dependent Kinases; Cyclins; Gene Expression Regulation; Humans; Neoplasms; Neuroprotective Agents; Parkinson Disease; Protein Kinase Inhibitors; Saccharomyces cerevisiae; Stroke

2021

Other Studies

39 other study(ies) available for cardiovascular-agents and Parkinson-Disease

Article	Year
[Clinical experiences in the treatment of spastic conditions of the skeletal musculature with Sanoma]. Die Medizinische Welt, 1962, Jul-21, Volume: 29 Topics: Cardiovascular Agents; Disease; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Muscle, Skeletal; Muscles; Muscular Diseases; Parkinson Disease	1962
The treatment of the Parkinson's syndrome with special reference to the value of aturbane. The British journal of clinical practice, 1960, Volume: 14 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease	1960
[Parkinzan therapy of patients with parkinsonism]. Sovetskaia meditsina, 1960, Volume: 24 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1960
[Experiences in the treatment of parkinsonism & other extrapyramidal disorders]. Die Medizinische, 1959, Feb-28, Volume: 4, Issue:9 Topics: Basal Ganglia Diseases; Cardiovascular Agents; Disease; Extrapyramidal Tracts; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1959
[Systematology of medical therapy in Parkinson's disease]. Munchener medizinische Wochenschrift (1950), 1959, Feb-27, Volume: 101, Issue:9 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease	1959
[Experiences with akineton in ambulant neurological practice]. Munchener medizinische Wochenschrift (1950), 1959, Mar-06, Volume: 101, Issue:10 Topics: Biperiden; Cardiovascular Agents; Databases, Genetic; Muscle Relaxants, Central; Parkinson Disease	1959
[Experiences with a new drug for control of parkinsonism, keithon]. Die Medizinische, 1959, Apr-11, Volume: 4, Issue:15 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1959
[Observations in treatment of parkinsonism with aturban]. Wiener medizinische Wochenschrift (1946), 1959, May-02, Volume: 109, Issue:18 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1959
[Medicinal treatment of parkinsonism]. Wiener medizinische Wochenschrift (1946), 1959, May-30, Volume: 109, Issue:22 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1959
Trial of a new remedy (Ciba 10870) in Parkinsonism. British medical journal, 1958, Apr-19, Volume: 1, Issue:5076 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1958
[Treatment of Parkinson's disease]. El Dia medico, 1958, Mar-10, Volume: 30, Issue:11 Topics: Anti-Allergic Agents; Belladonna Alkaloids; Cardiovascular Agents; Histamine H1 Antagonists; Muscle Relaxants, Central; Parkinson Disease	1958
Treatment of Parkinsonism. British medical journal, 1958, Jun-28, Volume: 1, Issue:5086 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1958
[Treatment of Parkinson's syndrome with aturban; preliminary report]. Schweizerische medizinische Wochenschrift, 1958, May-10, Volume: 88, Issue:19 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease	1958
[Cogentin, a new preparation for treatment of parkinsonism; preliminary report]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1958, Apr-01, Volume: 78, Issue:7 Topics: Benztropine; Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1958
[Experiences with the anti-parkinsonian drug akineton]. Wiener klinische Wochenschrift, 1958, Apr-11, Volume: 70, Issue:15 Topics: Biperiden; Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease	1958
Anti-Parkinson drugs and their relationship to glaucoma. Bulletin. Georgetown University. Medical Center, 1958, Volume: 12, Issue:1 Topics: Antiparkinson Agents; Cardiovascular Agents; Glaucoma; Muscle Relaxants, Central; Parkinson Disease; Trihexyphenidyl	1958
[Akineton psychoses]. Deutsche medizinische Wochenschrift (1946), 1958, Aug-15, Volume: 83, Issue:33 Topics: Biperiden; Cardiovascular Agents; Mental Disorders; Muscle Relaxants, Central; Parkinson Disease; Psychoses, Substance-Induced; Psychotic Disorders	1958
[Aturban (phenglutarimide), a new therapeutic drug for parkinsonism; comparative investigation on the therapy of parkinsonism]. Schweizerische medizinische Wochenschrift, 1958, Jul-26, Volume: 88, Issue:30 Topics: Cardiovascular Agents; Glutethimide; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1958
Parkinsonism: drug therapy; neurosurgical therapy. Postgraduate medicine, 1958, Volume: 24, Issue:6 Topics: Cardiovascular Agents; Humans; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders; Psychosurgery; Trihexyphenidyl	1958
[The benztropine methanesulfonate anti Parkinsonian agent]. Revista de la Asociacion Medica Argentina, 1958, Volume: 72, Issue:9 Topics: Benztropine; Cardiovascular Agents; Mesylates; Muscle Relaxants, Central; Parkinson Disease	1958
[Keithon for therapy of parkinsonism]. Medizinische Monatsschrift, 1957, Volume: 11, Issue:12 Topics: Cardiovascular Agents; Diphenhydramine; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1957
Ethopropazine (parsidol) hydrochloride in treatment of paralysis agitans; posology, method of administration, and effects. Journal of the American Medical Association, 1956, Feb-04, Volume: 160, Issue:5 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Phenothiazines; Salts	1956
Quantitative measurement of therapy in paralysis agitans. Journal of the American Medical Association, 1956, Feb-04, Volume: 160, Issue:5 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease	1956
Parsidol in the treatment of Parkinson's syndrome. Bulletin of the Los Angeles Neurological Society, 1956, Volume: 21, Issue:2 Topics: Antipsychotic Agents; Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Phenothiazines	1956
[An observation on the treatment of Parkinson's syndrome; results with the new drug ParKS 12]. Schweizerische medizinische Wochenschrift, 1956, Mar-31, Volume: 86, Issue:13 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Piperidines; Trihexyphenidyl	1956
Parkinsonism: treatment with curare. Annals of internal medicine, 1956, Volume: 45, Issue:5 Topics: Cardiovascular Agents; Curare; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders; Trihexyphenidyl	1956
[Therapeutic activity of a new drug, M.G. 1229, 4-(gamma-diethylaminopropyl)-hydroxydiphenylethane, in the parkinsonian syndrome]. Gazzetta medica italiana, 1956, Volume: 115, Issue:10 Topics: Cardiovascular Agents; Gamma Rays; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1956
[Myoparkil: a new antiparkinsonian drug; report on clinical findings]. Rivista sperimentale di freniatria e medicina legale delle alienazioni mentali, 1956, Oct-01, Volume: 80, Issue:4 Topics: Antiparkinson Agents; Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease	1956
[Benztropine methanesulfonate in the treatment of parkinsonism]. Prensa medica argentina, 1956, Dec-14, Volume: 43, Issue:50 Topics: Benztropine; Cardiovascular Agents; Mesylates; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1956
NEW AND nonofficial remedies: cycrimine hydrochloride. Journal of the American Medical Association, 1955, Feb-05, Volume: 157, Issue:6 Topics: Cardiovascular Agents; Muscarinic Antagonists; Muscle Relaxants, Central; Parkinson Disease; Piperidines	1955
[Symptomatic therapeutic effect of cycrimine HCl in parkinsonian syndromes]. La Presse medicale, 1955, Mar-12, Volume: 63, Issue:19 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders; Piperidines	1955
[Treatment of parkinsonism with special reference to a new drug]. Jornal do medico, 1954, Nov-13, Volume: 25, Issue:616 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1954
Acute hallucinosis secondary to pagitane hydrochloride administration. The New England journal of medicine, 1954, Dec-23, Volume: 251, Issue:26 Topics: Cardiovascular Agents; Hallucinations; Muscarinic Antagonists; Muscle Relaxants, Central; Parkinson Disease; Psychotic Disorders; Salts	1954
The use of benzotropine sulfonate in the treatment of parkinsonism. The Medical annals of the District of Columbia, 1953, Volume: 22, Issue:5 Topics: Alkanesulfonates; Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1953
The treatment of parkinsonism with a new antispasmodic compound. Medical bulletin (Ann Arbor, Mich.), 1953, Volume: 19, Issue:3 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parasympatholytics; Parkinson Disease; Parkinsonian Disorders; Piperidines	1953
[Activity of kemadrin on the symptoms of Parkinson's disease; comparison with other therapeutics]. La Presse medicale, 1953, Jan-31, Volume: 61, Issue:7 Topics: Cardiovascular Agents; Coal Tar; Muscle Relaxants, Central; Parkinson Disease; Procyclidine	1953
Evaluation of a new agent in the treatment of parkinsonism. Proceedings of the staff meetings. Mayo Clinic, 1953, Apr-08, Volume: 28, Issue:7 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders; Piperidines	1953
Antispasmodic compound 08958 in treatment of paralysis agitans. Journal of the American Medical Association, 1953, Oct-24, Volume: 153, Issue:8 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parasympatholytics; Parkinson Disease	1953
Kemadrin in postencephalitic parkinsonism. Lancet (London, England), 1952, Mar-22, Volume: 1, Issue:6708 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinson Disease, Postencephalitic; Procyclidine	1952